Researchers at the Icahn School of Medicine at Mount Sinai, led by Nina Bhardwaj, MD, Ph.D., Ward-Coleman Chair in Cancer ...

With the first therapeutic ... cancer vaccines, with more than ten such products — designed to confer active, specific immunotherapy directed against tumour-associated antigens — in Phase III ...

In the absence of biomarkers of intermediate response, careful evaluation of clinical data from trials involving therapeutic cancer vaccines in development may help to delineate a treatment ...

A vaccine for pancreatic cancer could serve as a promising new therapy. At Memorial Sloan ... Results from the phase 1 clinical trial, published in the journal Nature, revealed that the vaccine ...

New results from the phase 1 clinical trial, now published in the journal Nature, show that the therapeutic cancer vaccine activated tumor-specific immune cells that persisted in the body up to nearly ...

These formulations and combinations are under evaluation for a wide range of vaccine candidates in clinical trials. Here we describe cancer vaccine candidates using MPL adjuvant in the most ...

There are more than 400 ongoing trials and more than 200 in the works, according to Citeline data. Therapeutic cancer vaccines differ from more traditional vaccines such as the human ...

Closing in on a first approval There are still no approved therapeutic cancer vaccines. However, clinical trials are bringing vaccine candidates closer than ever to the point of validation and ...